MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients

BACKGROUND: Dopaminergic agonist cabergoline (CAB) has been used in pharmacological treatment of Cushing’s disease (CD). The effect is attributed to the frequent expression of subtype 2 dopamine receptor in corticotropic tumors. However, in vivo studies demonstrated normalization of urinary cortisol...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Ana Julia Garcia, Andrade, Natália Xavier S, Musolino, Nina Rosa de Castro, Cescato, Valter Angelo Sperling, da Silva, Gilberto Ochman, Fragoso, Maria Candida Barisson Villares, Bronstein, Marcello Delano, Machado, Marcio Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209226/
http://dx.doi.org/10.1210/jendso/bvaa046.572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209226/
http://dx.doi.org/10.1210/jendso/bvaa046.572

Ejemplares similares